Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Systemic mastocytosis (SM) is a hematopoietic neoplasm characterized by pathologic expansion of tissue mast cells in one or more extracutaneous organs. In most children and most adult patients, skin involvement is found. Childhood patients frequently suffer from cutaneous mastocytosis without systemic involvement, whereas most adult patients are diagnosed as suffering from SM. In a smaller subset of patients, SM without skin lesions develops which is a diagnostic challenge. In the current article, a diagnostic algorithm for patients with suspected SM is proposed. In adult patients with skin lesions and histologically confirmed mastocytosis in the skin (MIS), a bone marrow biopsy is recommended regardless of the serum tryptase level. In adult patients without skin lesions who are suffering from typical mediator-related symptoms, the basal serum tryptase level is an important diagnostic parameter. In those with slightly elevated tryptase (15-30 ng/ml), additional non-invasive investigations, including a KIT mutation analysis of peripheral blood cells and sonographic analysis, is performed. In adult patients in whom i) KIT D816V is detected or/and ii) the basal serum tryptase level is clearly elevated (> 30 ng/ml) or/and iii) other clinical or laboratory features are suggesting the presence of occult mastocytosis, a bone marrow biopsy should be performed. In the absence of KIT D816V and other indications of mastocytosis, no bone marrow investigation is required, but the patient's course and the serum tryptase levels are examined in the follow-up.

[1]  G. Nilsson,et al.  European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives , 2012, Wiener klinische Wochenschrift.

[2]  P. Valent,et al.  Diagnosis, progression patterns and prognostication in mastocytosis , 2012, Expert review of hematology.

[3]  P. Valent,et al.  Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience , 2011, International Archives of Allergy and Immunology.

[4]  M. Triggiani,et al.  Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal , 2011, International Archives of Allergy and Immunology.

[5]  P. Valent,et al.  Mast cell activation syndrome: Proposed diagnostic criteria. , 2010, The Journal of allergy and clinical immunology.

[6]  P. Valent,et al.  Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives , 2010, Expert review of hematology.

[7]  A. Órfão,et al.  Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. , 2010, The Journal of allergy and clinical immunology.

[8]  A. Tefferi,et al.  WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. , 2010, Blood.

[9]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[10]  G. Passalacqua,et al.  Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. , 2009, The Journal of allergy and clinical immunology.

[11]  E. Jassem,et al.  Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis , 2009, Allergy.

[12]  D. Metcalfe Mast cells and mastocytosis. , 2008, Blood.

[13]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[14]  K. Sotlar,et al.  Mastocytosis: State of the Art , 2007, Pathobiology.

[15]  L. Schwartz Diagnostic value of tryptase in anaphylaxis and mastocytosis. , 2006, Immunology and allergy clinics of North America.

[16]  L. Schwartz,et al.  Prolonged elevation of serum tryptase in idiopathic anaphylaxis. , 2006, The Journal of allergy and clinical immunology.

[17]  K. Wolff,et al.  The European Competence Network on Mastocytosis , 2004, Wiener klinische Wochenschrift.

[18]  P. Valent,et al.  Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. , 2004, The Journal of allergy and clinical immunology.

[19]  P. Valent,et al.  Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. , 2003, Hematology/oncology clinics of North America.

[20]  J. Bennett,et al.  Diagnosis and treatment of systemic mastocytosis: state of the art , 2003, British journal of haematology.

[21]  J. Bennett,et al.  Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. , 2003, Leukemia research.

[22]  U. Lass,et al.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. , 2003, The American journal of pathology.

[23]  A. Órfão,et al.  Mastocytosis: current concepts in diagnosis and treatment , 2002, Annals of Hematology.

[24]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[25]  P. Valent,et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. , 2001, Leukemia research.

[26]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[27]  P. Valent,et al.  Biology, classification and treatment of human mastocytosis. , 1996, Wiener klinische Wochenschrift.